Author
Listed:
- Harish Potu
(University of Michigan School of Medicine and Comprehensive Cancer Center)
- Luke F. Peterson
(University of Michigan School of Medicine and Comprehensive Cancer Center)
- Malathi Kandarpa
(University of Michigan School of Medicine and Comprehensive Cancer Center)
- Anupama Pal
(University of Michigan School of Medicine and Comprehensive Cancer Center)
- Hanshi Sun
(University of Michigan School of Dentistry)
- Alison Durham
(University of Michigan School of Medicine)
- Paul W. Harms
(University of Michigan School of Medicine)
- Peter C. Hollenhorst
(Medical Sciences Program, Indiana University Bloomington)
- Ugur Eskiocak
(Howard Hughes Medical Institute, University of Texas Southwestern Medical Center
Present address: Compass Therapeutics, 450 Kendall Street, Cambridge, Massachusetts 02142, USA)
- Moshe Talpaz
(University of Michigan School of Medicine and Comprehensive Cancer Center)
- Nicholas J. Donato
(University of Michigan School of Medicine)
Abstract
ETS transcription factors are commonly deregulated in cancer by chromosomal translocation, overexpression or post-translational modification to induce gene expression programs essential in tumorigenicity. Targeted destruction of these proteins may have therapeutic impact. Here we report that Ets-1 destruction is regulated by the deubiquitinating enzyme, Usp9x, and has major impact on the tumorigenic program of metastatic melanoma. Ets-1 deubiquitination blocks its proteasomal destruction and enhances tumorigenicity, which could be reversed by Usp9x knockdown or inhibition. Usp9x and Ets-1 levels are coincidently elevated in melanoma with highest levels detected in metastatic tumours versus normal skin or benign skin lesions. Notably, Ets-1 is induced by BRAF or MEK kinase inhibition, resulting in increased NRAS expression, which could be blocked by inactivation of Usp9x and therapeutic combination of Usp9x and MEK inhibitor fully suppressed melanoma growth. Thus, Usp9x modulates the Ets-1/NRAS regulatory network and may have biologic and therapeutic implications.
Suggested Citation
Harish Potu & Luke F. Peterson & Malathi Kandarpa & Anupama Pal & Hanshi Sun & Alison Durham & Paul W. Harms & Peter C. Hollenhorst & Ugur Eskiocak & Moshe Talpaz & Nicholas J. Donato, 2017.
"Usp9x regulates Ets-1 ubiquitination and stability to control NRAS expression and tumorigenicity in melanoma,"
Nature Communications, Nature, vol. 8(1), pages 1-14, April.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14449
DOI: 10.1038/ncomms14449
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_ncomms14449. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.